Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens-Reference-Cited by-同舟云学术

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

Published:2013-10 Issue:5 Volume:14 Page:216-223
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Mills Anthony M.,Cohen Calvin,DeJesus Edwin,Brinson Cynthia,Williams Scott,Yale Kitty L.,Ramanathan Srini,Wang Maggie H.,White Kirsten,Chuck Susan K.,Cheng Andrew K.

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/hct1405-216

Reference15 articles.

1. Efavirenz: a decade of clinical experience in the treatment of HIV

2. Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008

3. Neuropsychiatric side effects of efavirenz therapy

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical considerations when switching antiretroviral therapy;Expert Review of Clinical Pharmacology;2024-06-17

2. Pill Burden: A Major Barrier to HAART Adherence and Fixed Dose Combinations (FDCS) as its Solution – A Mini-Review;Current HIV Research;2024-05

3. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen;British Journal of Clinical Pharmacology;2023-08-16

4. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies;British Journal of Clinical Pharmacology;2023-03

5. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12